HeartBeam Patent Expands Cardiac Monitoring Platform with Heart Failure and Structural Heart Disease Capabilities

HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, has received a new U.S. patent covering the integration of acoustic sensing and thoracic impedance measurement into its credit card-sized, cable-free ECG device. The expanded capabilities are designed to support future applications in structural heart disease and heart failure monitoring by enabling the device to function as a digital stethoscope and assess fluid accumulation in the chest without changing its existing form factor.

The patent strengthens HeartBeam’s intellectual property portfolio by adding capabilities that could enable earlier detection of heart valve abnormalities and fluid congestion in heart failure patients through a portable, patient-operated device. The company said the patent advances its strategy of developing a multi-modal ambulatory cardiac sensing platform and expands its global patent portfolio to 26 issued patents spanning signal acquisition, ECG synthesis algorithms, diagnostic applications and device hardware.

This development is significant for Texas-based healthcare innovation and the broader medical technology industry. HeartBeam’s platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management.

The company’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025. HeartBeam holds over 20 issued patents related to technology enablement. For more information, refer to the company’s cleared indications for use at https://www.heartbeam.com/indications.

The patent expansion positions HeartBeam to potentially impact the management of heart failure and structural heart disease, conditions that affect millions of patients nationwide. By enabling earlier detection and continuous monitoring through a portable device, HeartBeam’s technology could reduce hospitalizations and improve patient outcomes, ultimately lowering healthcare costs. The integration of acoustic sensing and impedance measurement into a cable-free ECG device represents a step forward in ambulatory cardiac monitoring, offering a comprehensive diagnostic tool for patients and providers.

For investors and industry observers, this patent reinforces HeartBeam’s commitment to innovation and its growing intellectual property portfolio. The company’s progress in obtaining FDA clearances and expanding its technology platform suggests a trajectory toward broader clinical adoption. As HeartBeam continues to develop its multi-modal sensing platform, the potential for new applications in cardiac care remains significant.